Björn Redfors et al. JACEP 2017;j.jacep

Slides:

Advertisements

Similar presentations

AF and the New Oral Anti-Coagulants

Advertisements

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Percutaneous Coronary Intervention Complications.

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.

Date of download: 7/10/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Choice of Antithrombotic Therapy for Stroke Prevention.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Gastrointestinal Bleeding in Patients With Atrial.

Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated with Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.

Covering the Bases in Cardioversion

CHA2DS2-VASc Scoring System General AF Treatment Guidance.

Oana Dickinson et al. JACEP 2016;2:

ACTIVE A Effects of Addition of Clopidogrel to Aspirin in Patients with Atrial Fibrillation who are Unsuitable for Vitamin K Antagonists.

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

Prakash Harikrishnan et al. JACEP 2015;1:

Prakash Harikrishnan et al. JACEP 2015;1:

Nat. Rev. Cardiol. doi: /nrcardio

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

Up to Date on Which NOAC for Which Patient

Revealing Characteristics of Patients at High Risk for Developing Atrial Fibrillation.

Endothelial Dysfunction in Patients With Lone AF and AF Patients With Comorbidities Compared With That in Controls Comparisons are shown among control.

Masatoshi Yamazaki et al. JACEP 2015;1:

Waddah Maskoun et al. JACEP 2016;2:

Kenshi Hayashi et al. JACEP 2016;2:

Tom F. Brouwer et al. JACEP 2016;2:89-96

Ashish Shukla et al. JACEP 2015;1:41-51

Tom F. Brouwer et al. JACEP 2016;2:

Identifying High-Risk AF Patients

Adam B. Greenbaum et al. JACEP 2015;1:

David F. Katz et al. JACEP 2016;j.jacep

Pablo B. Nery et al. JACEP 2016;2:

Michael G. Klein et al. JACEP 2016;2:

Muhammad Shahreyar et al. JACEP 2016;j.jacep

Junjie Zhang et al. JACEP 2017;3:

Prakash Harikrishnan et al. JACEP 2015;1:

Peter F. Aziz et al. JACEP 2015;1:62-70

Michael G. Klein et al. JACEP 2016;j.jacep

Mitsunori Maruyama et al. JACEP 2017;3:

Mohit K. Turagam et al. JACEP 2017;3:

Mu Qin et al. JACEP 2017;j.jacep

Leonard M. Rademakers et al. JACEP 2016;2:

Prakash Harikrishnan et al. JACEP 2015;1:

Philippe Taghji et al. JACEP 2017;j.jacep

Yoshitaka Kimura et al. JACEP 2016;2:

Emilce Trucco et al. JACEP 2018;j.jacep

Vittorio Calzolari et al. JACEP 2017;3:

Junjie Zhang et al. JACEP 2017;3:

Kenshi Hayashi et al. JACEP 2016;2:

David F. Katz et al. JACEP 2017;3:20-28

Björn Redfors et al. JACEP 2017;j.jacep

Moussa Mansour et al. JACEP 2016;j.jacep

5 Good Minutes on Atrial Fibrillation-related Stroke

Anna Björkenheim et al. JACEP 2017;j.jacep

Vittorio Calzolari et al. JACEP 2017;3:

Ayman A. Hussein et al. JACEP 2017;3:1-9

Mintu P. Turakhia et al. JACEP 2016;2:

Simon W. Rabkin et al. JACEP 2017;3:

K.R. Julian Chun et al. JACEP 2017;3:

Björn Redfors et al. JACEP 2017;j.jacep

Jose C. Pachon M. et al. JACEP 2015;1:

Glenn N. Levine et al. JACC 2011;58:e44-e122

Incidence rates and HRs for total cardiovascular events and stroke stratified by the TCF7L2-rs polymorphism and the dietary intervention group after.

Kaplan-Meier survival curves for non-fatal stroke or mortality based on IMRS categories among (A) women (p-trend

Davide Capodanno et al. JCIN 2009;2:

Jeffrey J. Teuteberg et al. JCHF 2015;3:

Pamela E. Scott et al. JACC 2018;71:

Davide Capodanno et al. JCIN 2009;2:

Maxime Berthelot-Richer et al. JIMG 2016;9:

Maria R. Costanzo et al. JCHF 2016;4:

Gianluigi Savarese et al. JCHF 2016;4:

Kaplan-Meier survival curves of the IMRS association with non-fatal stroke/mortality (stroke-free survival) in women with AF, stratified by CHA2DS2-VASc.

Balancing bleeding in brain metastases

The CHA(2)DS2-(VASc) stroke risk and HAS-BLED bleeding risk index are calculated by totalling the scores for each risk factor present.68–71 The lower graph.

Presentation transcript:

Björn Redfors et al. JACEP 2017;j.jacep.2017.04.024 Relationship Between Yearly Incidence of Major Bleeding and Risk Scores in Patients With Contraindication to OAC (A) Yearly incidence in major bleeding and intracranial bleeding among the study cohort of OAC-naive patients with contraindication to OAC (n = 43,248; blue). Expected yearly major bleeding rates (defined as fatal bleeding, symptomatic bleeding in a critical area or organ, or bleeding causing a fall in hemoglobin of ≥20 g/L or leading to transfusion of ≥2 units of whole blood or red cells#) in a general population of AF patients who are treated on OAC (red). (B) Yearly incidence of major bleeding, defined as any gastrointestinal, genitourinary, or respiratory tract bleeding that required transfusion or surgical intervention, by CHA2DS2-VASc score for the study cohort of OAC-naive patients with contraindication to OAC (n = 43,248; blue). Also presented are expected yearly major bleeding rates$ (defined as fatal bleeding, symptomatic bleeding in a critical area or organ, or bleeding causing a fall in hemoglobin of ≥20 g/L or leading to transfusion of ≥2 U of whole blood or red cells) in a general population of AF patients who are treated on OAC (red). The latter includes also intracranial bleeding. In the study population the yearly incidence of intracranial bleeding per CHA2DS2-VASc category, in ascending order, was 2.4%, 2.8%, 3.5%, 3.7%, 3.7%, 3.7%, 4.7%, 4.6%, 3.5%, and 4.5%. † Adjusted stroke rates in the general population are based on data from Roldan et al. (15). # Major bleeding in the report by Roldan et al. (15) includes intracranial bleeds, whereas we report separately on intracranial bleeding. Thus, the yearly rates of major bleeding are underestimated in our study cohort compared with Roldan et al. (15) $Roldan et al. (15) reported total number of events per CHA2DS2-VASc category, with a median follow-up of 996 days. We estimated yearly rates by assuming event rates per 996 days in each CHA2DS2-VASc category. Abbreviations as in Figure 1. Björn Redfors et al. JACEP 2017;j.jacep.2017.04.024 2017 American College of Cardiology Foundation